BSEM (BioStem Technologies) Inventories, Finished Goods: $2.4 Mil (As of Sep. 2025)


BSEM BioStem Technologies Inc BSEM
49 GF Score
Price $3.26
GF Value $142.75
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioStem Technologies Inventories, Finished Goods?

BioStem Technologies BSEM -0.76% 49 Inventories, Finished Goods is $2.4 Mil as of Sep. 2025. GuruFocus rates BSEM with a GF Score™ of 49/100 and a GF Value™ of $142.75 (Possible Value Trap). The stock has 3 warning signs investors should review.

BioStem Technologies's quarterly finished goods declined from Sep. 2024 ($1.8 Mil) to Dec. 2024 ($1.6 Mil) but then increased from Dec. 2024 ($1.6 Mil) to Sep. 2025 ($2.4 Mil).

BioStem Technologies's annual finished goods increased from Dec. 2022 ($0.3 Mil) to Dec. 2023 ($0.6 Mil) and increased from Dec. 2023 ($0.6 Mil) to Dec. 2024 ($1.6 Mil).

BioStem Technologies Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for BioStem Technologies's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioStem Technologies Inventories, Finished Goods Chart

BioStem Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.00 0.35 0.59 1.65

BioStem Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Sep21 Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Sep24 Dec24 Sep25
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.59 1.76 1.65 2.42
BSEM
49GF Score
BioStem Technologies Inc BSEM
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioStem Technologies Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $2.4 Mil mean?
BioStem Technologies (BSEM) has a Inventories, Finished Goods of $2.4 Mil as of Sep. 2025. Finished goods are inventory items that are complete and ready to be sold. View historical data on BioStem Technologies and its competitors.
Is BioStem Technologies' Inventories, Finished Goods too high?
BioStem Technologies' current Inventories, Finished Goods is $2.4 Mil. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Inventories, Finished Goods compare to XLO and TCRX?
BioStem Technologies' Inventories, Finished Goods of $2.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on BioStem Technologies and its competitors. BioStem Technologies's current Inventories, Finished Goods is $2.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $142.75, compared to a current price of $3.26 — trading 97.7% below its estimated fair value. The current Inventories, Finished Goods is $2.4 Mil. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Inventories, Finished Goods is $2.4 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioStem Technologies (BSEM) Overvalued in 2026?

Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued. The current stock price of $3.26 is trading 97.7% below its estimated GF Value™ of $142.75. GuruFocus considers BioStem Technologies to be Possible Value Trap.

Key valuation signals for BSEM:

  • Inventories, Finished Goods: $2.4 Mil
  • GF Value™: $142.75 vs. price of $3.26 (97.7% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioStem Technologies Business Description

Address 2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score

Get the complete analysis for BSEM

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.26
Price
$142.75
GF Value